The new indication allows durvalumab, in combination with carboplatin and paclitaxel, to be used as a first-line treatment for adults with primary, advanced, or recurrent endometrial cancer who are candidates for systemic therapy. Shares of AstraZeneca Pharma India Ltd ended at ₹8,890, up by ₹18.30, or 0.21%, on the BSE.
